Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly (NYSE:LLY) has filed lawsuits against four telehealth platforms that the pharma giant alleges are selling compounded versions of its blockbuster GLP-1/GIP receptor agonist tirzepatide ...

The weight loss drug market could grow to $500 billion over the next decade. Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are ...

JACKSONVILLE — Lilly Ledbetter grew up poor in the Possum Trot community north of Jacksonville. Despite her oft-drunken father and her downtrodden mother, she graduated from high school ...

Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds ...

In November 2023, influencer Lilly Sabri‘s picture-perfect life crumbled when she woke up to find thousands of messages from women who believed her fiancé, Alex Tyrwhitt, had cheated on her ...

Eli Lilly is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.Trading at $852 per share, LLY ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Pharmaceutical giant Eli Lilly and Co. sued Willow Health Services and three other companies in federal court in New Jersey and California, accusing them of selling unapproved compounded ...